Trial reportFrontiers in global women's health2026
Article title efficacy and safety of romosozumab in postmenopausal women with osteoporosis previously treated with antiresorptive drugs: a prospective observational study and literature review.
Trial report in Frontiers in global women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The number of patients receiving long-term antiresorptive drugs for postmenopausal osteoporosis is increasing worldwide. However, there is limited evidence on when and how to discontinue or switch these drugs. This study evaluated the efficacy of romosozumab in women who had been treated with antiresorptive drugs for over three years. Methods: This was a prospective observational non-randomized study analyzing patients with postmenopausal osteoporosis, which was registered in the jRCT (No. 1051210070). Postmenopausal women with lumbar and femoral neck bone mineral density (BMD) below -2.5 SD, as measured by dual-energy x-ray absorptiometry (DXA), despite more than 36 months of antiresorptive treatment, were recruited. They received romosozumab along with calcium and active vitamin D supplementation for 12 months. BMD and bone turnover markers, including serum P1NP and I-CTP, were periodically monitored. Results: Twenty-one patients (median age: 73 years) were observed for a median of 833 days. Baseline BMD was 0.77 g/cm² at the lumbar spine (T-score: -2.0) and 0.49 g/cm² at the femoral neck (T-score: -2.8). After 12 months, lumbar BMD significantly increased by 6.2% ( Conclusion: Romosozumab significantly increased lumbar BMD and bone turnover markers in patients previously treated with antiresorptive drugs, supporting its use as a potential treatment option. Clinical Trial Registration: https://jrct.mhlw.go.jp/, identifier No. 1051210070.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.